This report provides an overview of the evolving treatment landscape for Graft versus Host Disease (GvHD), a serious complication associated with allogeneic stem cell and bone marrow transplants. The global GvHD market, valued at approximately USD 626 million in 2022, is projected to reach USD 1.7 billion by 2028, growing at a CAGR of over 28.5%. While corticosteroids remain the dominant treatment option, the market is becoming increasingly competitive with the emergence of new therapies and pipeline candidates. Key growth drivers include the rising prevalence of cancer, an expanding geriatric population, increasing numbers of bone marrow and allogeneic transplants, and a growing incidence of chronic GvHD. The report highlights major market participants, upcoming therapies, and opportuniti

Join for free to read